Atamyo Therapeutics Announces the Dosing of a Fourth Patient with ATA-200 in an Ongoing LGMD-R5 Clinical Trial, Supported by CureSCG

Atamyo Therapeutics announces continued progress in its ongoing clinical trial of ATA-200, with the recent dosing of a fourth patient, marking an important milestone in the development of its gene therapy for γ-sarcoglycan related limb girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5).

Atamyo acknowledges the support of CureSCG, whose contribution has played an important role in supporting the ongoing clinical trial. CureSCG is a patient advocacy organization committed to accelerating research efforts in LGMD sarcoglycanopathies and supporting families affected by the disease. Their involvement reflects a shared commitment to advancing therapeutic innovation for the patient community. 

 “This new step reflects the coordinated efforts of clinical teams, the trust of patients, and the commitment of our partners. The support from CureSCG demonstrates the strength of a community working together to advance therapeutic options for individuals living with γSGC.” — Angela Columbano, CEO, Atamyo Therapeutics.

“We are proud to contribute to the advancement of this important clinical program and deeply grateful to the Dion Foundation for initiating this effort in collaboration with Atamyo. We also thank Atamyo and the clinical teams for their continued dedication. Supporting the dosing of the fourth patient represents a meaningful step forward for the γ-SGC community, and we remain committed to helping move this research forward for families who are waiting for treatment options.” — Rana Abu Khadra, Co-Founder, CureSCG.

CureSCG intends to continue supporting the program as it advances, both within and outside the United States, in alignment with its long term mission to advance scientific and clinical efforts for individuals living with LGMD sarcoglycanopathies.

Atamyo remains firmly committed to advancing safe and innovative gene therapies for rare neuromuscular diseases and looks forward to the continued progression of the γSGC clinical program.